<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886884</url>
  </required_header>
  <id_info>
    <org_study_id>20160686</org_study_id>
    <secondary_id>1R01HL134558-01</secondary_id>
    <nct_id>NCT02886884</nct_id>
  </id_info>
  <brief_title>Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects</brief_title>
  <acronym>ACESO</acronym>
  <official_title>A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via&#xD;
      infusion therapy for diabetic subjects with endothelial dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Related Serious Adverse Events (TE-SAEs)</measure>
    <time_frame>Up to one month (post infusion)</time_frame>
    <description>TE-SAEs are defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities. TE-SAEs will be assessed by treating physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EPC-CFU levels</measure>
    <time_frame>Up to 12 months (post infusion)</time_frame>
    <description>Endothelial Progenitor Cell Colony Forming Units (EPC-CFU) will be assessed from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Marker Levels</measure>
    <time_frame>Up to 12 months (post infusion)</time_frame>
    <description>C-Reactive Protein (CRP) levels will be assessed from blood samples and reported in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Angiogenic Factor Levels</measure>
    <time_frame>Up to 12 months (post infusion)</time_frame>
    <description>Circulating Angiogenic Factor levels including Vascular Endothelial Growth Factor (VEGF), Stem Cell Factor (SCF) and Stromal Cell-Derived Factor 1 (SDF-1) will be assessed from blood samples and reported in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow Mediated Diameter Percentage (FMD%)</measure>
    <time_frame>Up to 12 months (post infusion)</time_frame>
    <description>FMD will be assessed using brachial artery ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating Inflammatory Marker Levels</measure>
    <time_frame>Up to 12 months (post infusion)</time_frame>
    <description>Circulating inflammatory marker levels including Interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF) Alpha will be assessed from blood samples and reported in pg/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>20 million allogeneic hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight (8) subjects will be delivered via peripheral intravenous infusion of 20 million allogeneic Mesenchymal Human Stem Cells (hMSCs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 million hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight (8) subjects will be delivered via peripheral intravenous infusion of 100 million allogeneic Mesenchymal Human Stem Cells (hMSCs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 million Allogeneic Mesenchymal Human Stem Cells</intervention_name>
    <description>1 single intravenous infusion</description>
    <arm_group_label>20 million allogeneic hMSCs</arm_group_label>
    <other_name>allo-hMSCs</other_name>
    <other_name>stem cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 million Allogeneic Mesenchymal Human Stem Cells</intervention_name>
    <description>1 single intravenous infusion</description>
    <arm_group_label>100 million hMSCs</arm_group_label>
    <other_name>allo-hMSCs</other_name>
    <other_name>stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be ≥ 21 and &lt; 90 (inclusive) years of age.&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Have endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD &lt;7%).&#xD;
&#xD;
          -  Have an ejection fraction &gt; 45% by gated blood pool scan, two- dimensional&#xD;
             echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3&#xD;
             months.&#xD;
&#xD;
          -  Have Diabetes mellitus type 2 documented by hemoglobin adult type 1 component (A1C) &gt;&#xD;
             7% or on medical therapy for diabetes.&#xD;
&#xD;
          -  Females of childbearing potential must use two forms of birth control for the duration&#xD;
             of the study. Female subjects must undergo a blood or urine pregnancy test at&#xD;
             screening and within 36 hours prior to infusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        In order to participate in this study, a subject Must Not:&#xD;
&#xD;
          -  Be younger than 21 years or older than 90 years of age.&#xD;
&#xD;
          -  Have a baseline glomerular filtration rate &lt;35 ml/min 1.73m^2 estimated using the&#xD;
             Modification of Diet in renal disease (MDRD) formula.&#xD;
&#xD;
          -  Have an ejection fraction &lt;45% by gated blood pool scan, two-dimensional&#xD;
             echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the past year,&#xD;
             as documented by medical history.&#xD;
&#xD;
          -  Have poorly controlled blood glucose levels with hemoglobin A1C &gt; 8.5%.&#xD;
&#xD;
          -  Have a history of proliferative retinopathy or severe neuropathy requiring medical&#xD;
             treatment.&#xD;
&#xD;
          -  Have a hematologic abnormality as evidenced by hematocrit &lt; 25%, white blood cell &lt;&#xD;
             2,500/ul or platelet values &lt; 100,000/ul without another explanation.&#xD;
&#xD;
          -  Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times&#xD;
             the upper limit of normal.&#xD;
&#xD;
          -  Have a bleeding diathesis or coagulopathy (INR &gt; 1.3), cannot be withdrawn from&#xD;
             anticoagulation therapy, or will refuse blood transfusions.&#xD;
&#xD;
          -  Have Lymphadenectomy or Lymph node dissection in the right arm.&#xD;
&#xD;
          -  Be an organ transplant recipient or have a history of organ or cell transplant&#xD;
             rejection.&#xD;
&#xD;
          -  Have a clinical history of malignancy within the past 5 years (i.e., subjects with&#xD;
             prior malignancy must be disease free for 5 years), except curatively- treated basal&#xD;
             cell or squamous cell carcinoma, or cervical carcinoma.&#xD;
&#xD;
          -  Have a condition that limits lifespan to &lt; 1 year.&#xD;
&#xD;
          -  Have a history of drug or alcohol abuse within the past 24 months.&#xD;
&#xD;
          -  Be on chronic therapy with immunosuppressant medication, such as corticosteroids or&#xD;
             Tumor Necrosis Factor - alpha (TNFα) antagonists.&#xD;
&#xD;
          -  Be serum positive for HIV, Syphilis - VDRL (Confirmation with FTA-ABS if needed&#xD;
             (Syphilis)), hepatitis B surface antigen or viremic hepatitis C.&#xD;
&#xD;
          -  Be currently participating (or participated within the previous 30 days) in an&#xD;
             investigational therapeutic or device trial.&#xD;
&#xD;
          -  Be pregnant, nursing, or of childbearing potential while not practicing effective&#xD;
             contraceptive methods.&#xD;
&#xD;
          -  Any other condition that in the judgment of the Investigator would be a&#xD;
             contraindication to enrollment or follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua M Hare, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ISCI / University of Miami Miller School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>Interdisciplinary stem cell institute at the University of Miami website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Sponsor - Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Stem cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

